Weight Loss Drugs

Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why
Eli Lilly Q3 Earnings On Deck: Stock Split Rumors Heat Up With Weight Loss Gains (CORRECTED)
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?

Weight Loss Drugs Recent News

Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation. Other drugs also affected.
Weight-Loss Giant Novo Nordisk Tumbles To 200-Day Average Support: 'Weakness Could Be Buying Opportunity,' Analyst Says
Shares of Novo Nordisk are down 6% after Q2 results fell short of expectations; weight-loss drug sales disappoint.
Using Weight Loss Medications Such As Wegovy, Zepbound? Psychologist Warns Of Linked Eating Disorder Risks
Psychologists warn of increased eating disorders linked to popular GLP-1 weight loss drugs like Wegovy and Zepbound. Experts urge better screening and research to address potential risks.
What's Going On With HIMS Shares Today?
Hims & Hers Health experienced a significant decline in its stock price on Thursday. Here's what you need to know.
Novo Nordisk's Older Weight Loss Drug May Slow Cognitive Decline in Alzheimer's Patients, Small Study Shows Brain-Protecting Benefits
Liraglutide shows promise in slowing cognitive decline in Alzheimer's patients, reducing brain volume loss and offering neuroprotective benefits, according to a Phase 2b clinical trial presented at AAIC 2024.
Walt Disney, Eli Lilly, AST SpaceMobile, DexCom, Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Thursday, major U.S. indices showed mixed results. The Dow Jones Industrial Average increased by 0.2% to 39,935.07.
UK's NHS Prescribes Weight-Loss Drug Wegovy Less Than Expected Due To Service Shortages
The NHS has prescribed Wegovy far less often than expected due to a shortage of weight management clinics, highlighting significant challenges in meeting growing demand for the weight-loss drug.
Britain's Drug Regulator Approves Novo Nordisk's Weight Loss Drug Wegovy To Cut Heart Disease Risk In Obese Patients
The U.K. MHRA has approved Novo Nordisk's Wegovy (semaglutide) to prevent cardiovascular issues in overweight and obese adults with existing heart conditions. This new indication highlights Wegovy's role in reducing major adverse cardiovascular events by 20%.
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Pharmaceutical giants like Roche, Eli Lilly, Novo Nordisk, and Pfizer are racing to develop oral weight loss medications. These drugs promise to complement existing injectables, offering new hope in the fight against obesity.
Novo Nordisk Faces Setback in Netherlands Over Wegovy Insurance Coverage
Novo Nordisk expresses disappointment over the Dutch Health Care Institute's advice against including Wegovy in the Netherlands' basic insurance, citing unclear health benefits and high costs.
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996 trial results for type 2 diabetes and obesity. Get insights into the latest clinical trial data.
Using Ozempic, Zepbound Or Other Weight Loss Drugs? Inform Doctors Before Anesthesia Or Surgery, European Medicines Agency Issues Advisory
EMA advises patients on GLP-1 weight-loss drugs like Wegovy to inform their doctors before surgery due to potential respiratory risks. New warnings to be included in product information to ensure patient safety.
Bernie Sanders Targets High Prices of Ozempic and Wegovy In US
Senator Bernie Sanders is pushing Novo Nordisk to lower U.S. prices for weight-loss drugs Ozempic and Wegovy, as part of a broader effort to reduce drug costs and expand Medicare price negotiations.
Pfizer Advances Once-Daily Weight-Loss Pill As It Catches Up To Tap The Lucrative Market
Pfizer advances its once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, after positive Phase 1 pharmacokinetic study results. Dose optimization studies will follow in H2 2024, aiming to enhance obesity treatment options.
Ben & Jerry's Co-Founders Not Worried About Ozempic's Impact On Ice Cream Business: Here's Why
Ben Cohen and Jerry Greenfield, the co-founders of Ben & Jerry's, are not worried about the impact of weight-loss drugs on their ice cream business, despite the impending spin-off of their parent company Unilever's ice cream division.
Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs
Regeneron Pharmaceuticals released data from a Phase 1 study on garetosmab and trevogrumab at the ADA meeting, showing significant increases in lean mass and reductions in fat mass in healthy volunteers.
Will Novo Nordisk Building Fires Serve As A Catalyst For Eli Lilly? Redditors See A Stock Split For US Company 'Very Likely'
Eli Lilly's stock may rise due to supply issues at competitor Novo Nordisk, according to Reddit users. Its weight loss drug and upcoming FDA approval are also factors. Investors are optimistic about its future performance.
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market
Structure Therapeutics Obesity Candidate Is 'Very Competitive' To Eli Lilly's Orforglipron, Analyst Says
Structure Therapeutics reports positive 12-week Phase 2a obesity study results for GSBR-1290, showing a 6.2% weight loss. Cantor Fitzgerald maintains an Overweight rating with a $65 target
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk
New OZEM ETF offers investors exposure to weight-loss sector through top pharmaceutical companies Eli Lilly and Novo Nordisk, with potential for high growth but also risks.
Weight Loss Drug Market To Rocket To $130B By 2030 With Eli Lilly, Novo Nordisk In Lead: Goldman Sachs
Goldman Sachs re-rated Eli Lilly and Novo Nordisk, citing potential for weight-loss drugs. Global sales expected to reach $130B by 2030.
South Park Took On Crypto, AI Previously: Animated Comedy Targets Weight-Loss Drug Ozempic Next
Weight loss drugs get the new parody treatment in a "South Park" streaming special.
Wellness Platform Hims & Hers Health Adds GLP-1 Injections For Weight Loss, Stock Soars
Hims & Hers Health expands its weight loss offerings with GLP-1 injections and oral medication kits. Pricing starts at $79/month.

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved